The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canada.

_

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad

__

The biotechnology industry faces a number of challenges in 2008 if it is to enjoy the record levels it achieved in financing and deal-making last year, according to a new study.

Ernst & Young’s Beyond Borders: Global Biotechnology Report 2008 notes that last year biotech companies in the Americas and Europe raised more than $29.9 billion, while venture financing reached an all-time high, with investment totalling about $7.5 billion, fuelled by $5.5 billion raised in the USA and 72% growth in Canad